Duvelisib was the next PI3K inhibitor authorised via the FDA, also dependant on a section III randomized trial.130 The efficacy and safety profile with the drug appear comparable with those of idelalisib, if not somewhat advantageous. About option BTK inhibitors, there are numerous solutions in improvement, but only acalabrutinib is permitted from